文献速递妇科产科

接受艾多沙班或华法林治疗静脉血栓栓塞症的育龄女性异常阴道出血:Hokusai-VTE 研究的事后分析

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
PubMed 文献 · BJOG · 2018-07-20

该研究为 Hokusai-VTE 随机双盲试验的事后分析,纳入 50 岁以下因静脉血栓栓塞症接受艾多沙班(628 例)或华法林(665 例)治疗的女性。艾多沙班组异常阴道出血发生率为 15/100 人年(95%CI 11-19),高于华法林组的 9/100 人年(95%CI 6-12),风险比 1.7(95%CI 1.1-2.5)。大多数出血事件临床病程轻微,可保守处理。

要点

  • 艾多沙班组异常阴道出血发生率 15/100 人年,华法林组 9/100 人年,HR 1.7(95%CI 1.1-2.5)。
  • 大出血发生率艾多沙班组 1.3%(8 例) vs 华法林组 0.9%(3 例),OR 2.8(95%CI 0.8-10.8)。
  • 临床相关非大出血发生率艾多沙班组 8.4%(53 例) vs 华法林组 5.6%(37 例),OR 1.6(95%CI 1.0-2.4)。

核心结论

  • 接受艾多沙班治疗的女性异常阴道出血发生率高于接受华法林治疗的女性;大多数事件可保守处理且临床结局轻微。

研究设计与样本

  • Hokusai-VTE 研究的事后分析,该研究为多中心、随机、双盲试验,比较艾多沙班与华法林治疗急性症状性静脉血栓栓塞症。
  • 纳入 50 岁以下因静脉血栓栓塞症接受艾多沙班(628 例)或华法林(665 例)治疗的女性。
  • 收集异常阴道出血事件的诊断措施、治疗及临床结局数据。

主要发现

  • 异常阴道出血发生率艾多沙班组 15/100 人年(95%CI 11-19) vs 华法林组 9/100 人年(95%CI 6-12),风险比 1.7(95%CI 1.1-2.5)。
  • 大出血发生率艾多沙班组 1.3%(8 例) vs 华法林组 0.9%(3 例),OR 2.8(95%CI 0.8-10.8)。
  • 临床相关非大出血发生率艾多沙班组 8.4%(53 例) vs 华法林组 5.6%(37 例),OR 1.6(95%CI 1.0-2.4)。
  • 超过 85% 的阴道出血表现为月经过多。
  • 大出血常需治疗,超过 75% 的患者调整了抗凝治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE). DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE. POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE. METHODS: We collected data on diagnostic measures, treatment, and clinical outcome of abnormal vaginal bleeding events. MAIN OUTCOME MEASURES: Occurrence of major and clinically relevant nonmajor (CRNM) abnormal vaginal bleeding events. RESULTS: In all, 628 women aged under 50 years were treated with edoxaban and 665 with warfarin. The rate of abnormal vaginal bleeding was 15/100 person-years (py) (95% CI 11-19) in women receiving edoxaban and 9/100 py (95% CI 6-12) in the warfarin group (hazard ratio: 1.7, 95% CI 1.1-2.5). Major abnormal vaginal bleeding occurred in eight (1.3%) women on edoxaban and in three (0.9%) women receiving warfarin [odds ratio (OR) 2.8; 95% CI 0.8-10.8], and CRNM abnormal vaginal bleeding occurred in 53 (8.4%) women treated with edoxaban and in 37 (5.6%) on warfarin therapy (OR 1.6, 95% CI 1.0-2.4). Over 85% of all vaginal bleeds were characterised by heavy menstrual bleeding. Major bleeds frequently required treatment, and in more than 75% of patients anticoagulant therapy was adjusted. The severity of clinical presentation and course of major and CRNM bleeds was mild in most patients. CONCLUSIONS: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin. Reassuringly, most events could be managed conservatively and had a mild outcome. TWEETABLE ABSTRACT: Abnormal vaginal bleeding occurred more frequently in women treated with edoxaban than with warfarin.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Scheres L, Brekelmans M, Ageno W, et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG. 2018. PMID: 29940089. doi:10.1111/1471-0528.15388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。